According to the Israeli research institute, the mutant virus discovered in South Africa can “break through” the Pfizer vaccine’s protective net to a certain extent. However, the research has not yet been peer reviewed.
Reuters reported that Tel Aviv University and the Israeli medical service agency Clarit Institute released the latest research on Saturday (10th). The team divided 800 patients with Covid-19 into two batches. The batches are those who are still infected 14 days after receiving one or two doses of the Pfizer vaccine.
The study found that 1% of the study subjects were infected with a variant virus found in South Africa. Among them, patients who were still diagnosed after receiving two doses of the Pfizer vaccine were nearly eight times more likely to be infected with the variant virus than those who had not been vaccinated. The infection rates were respectively It is 5.4% and 0.7%.
Tel Aviv University expert Stern said that compared with unvaccinated patients, patients vaccinated with two doses are more likely to be infected with the variant virus found in South Africa. This means that the mutant virus can “break through” the protective effect of Pfizer vaccine to a certain extent.
However, the researchers also emphasized that due to the low infection rate of the variant virus found in South Africa in Israel, there are not many samples in this study, and it is impossible to infer the overall protective effect of the Pfizer vaccine against the variant virus. This research has not yet been peer reviewed. Pfizer and BioNTech of Germany have not yet commented on this.
According to reports, Pfizer and BioNTech stated on April 1 this year that the vaccine they produced was 91% effective in preventing coronaviruses, and added new clinical data to claim that the vaccine is effective against the variant virus found in South Africa.